adeno-associated virus serotype rh.10 vector expressing bevacizumab (REGENXBIO)

N/A

Report date: 2025/01/26 18:50:03

Base Information

Drug Nameadeno-associated virus serotype rh.10 vector expressing bevacizumab (REGENXBIO)

Drug Alias NameAAVrh.10BevMabadeno-associated virus vector-7 based gene therapy (RegenX Biosciences)adeno-associated virus serotype rh.10 vector expressing bevacizumab (RegenX)AMD-AAV7

ClassificationBiologics

Mechanisms of ActionVascular endothelial growth factor receptor antagonists

TargetsVascular endothelial growth factor receptor

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRegenxbio Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegenxbio Inc

Inactive CompaniesN/A

Active IndicationsMacular Degeneration

Inactive IndicationsN/A

Other Information

ATC CodeN/A